References
- Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology. 2003;49(1):1–11.
- Moutray T, Chakravarthy U. Age-related macular degeneration: current treatment and future options. Ther Adv Chronic Dis. 2011;2(5):325–331.
- Schargus M, Frings A. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol. 2020;14:897–904.
- Medeiros S, Mukamal R, Sridhar JS, et al. New treatments for age-related macular degeneration. American Academy of Ophthalmology. 2021. cited 2022 Aug 10, from https://www.aao.org/eye-health/tips-prevention/promising-new-treatments-amd
- Sabbagh O, Mehra A, Maldonado RS. Gene therapy in AMD: promises and challenges. Retina Specialist. 2020. cited 2022 Aug 10, from https://www.retina-specialist.com/article/gene-therapy-in-amd-promises-and-challenges
- Khanani AM, Thomas MJ, Aziz AA, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36(2):303–311.
- Moore NA, Bracha P, Hussain RM, et al. Gene therapy for age-related macular degeneration. Expert Opin Biol Ther. 2017;17(10):1235–1244. 2017.
- Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583–593.
- Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol ther. 2008;16(3):458–465.
- ClinicalTrials.gov. A phase 2, open-label study to explore the pharmacodynamics of two doses in two formulations of RGX-314 gene therapy administered via subretinal delivery in participants with neovascular age-related macular degeneration. ClinicalTrials.gov Identifier: NCT04832724. 2022. [cited 2022 Aug 10]. Available at: https://clinicaltrials.gov/ct2/show/NCT04832724
- Campochiaro PA. Gene therapy for neovascular AMD - regenxbio.com. 2022 [cited 2022 Oct 23]. https://www.regenxbio.com/wp-content/uploads/2022/10/RGX-314-AAO2022-SR-LTFU_Peter-C_FINAL_.pdf
- ClinicalTrials.gov. A phase 2, randomized, dose-escalation, ranibizumab-controlled study to evaluate the efficacy, safety, and tolerability of RGX-314 gene therapy delivered via one or two suprachoroidal space (SCS) injections in participants with neovascular age-related macular degeneration (nAMD) (AAVIATE). ClinicalTrials.gov Identifier: NCT04832724 2022 [cited 2022 Aug 10]. Available at: https://clinicaltrials.gov/ct2/show/NCT04514653
- “Regenxbio announces additional positive interim data from trials of RGX-314 for the treatment of WET AMD.” REGENXBIO Inc. 2022 [cited 2022 Aug 10]. https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-additional-positive-interim-data-trials-rgx.
- Dugel PU, Heier JS, Sarraf D, et al. Clinical trial download: data on a gene therapy for dry and wet AMD. A phase 1 clinical trial program is targeting both disease states. Retinalphysician.com. 2020 [cited 2022 Aug 10].https://www.retinalphysician.com/issues/2020/april-2020/clinical-trial-download-data-on-a-gene-therapy-for
- Desai D, Dugel PU. Complement cascade inhibition in geographic atrophy: a review. Eye. 2022;36:294–302.
- Pieramici D, Ehlers JP. ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: OPTIC Phase 1 Study Update. 2022 [cited 2022 Aug 10]. https://adverum.com/wp-content/uploads/2022/09/AAO_OPTIC-Presentation_26Sep22.pdf
- Askou AL, Alsing S, Benckendorff JNE, et al. Suppression of choroidal neovascularization by AAV-based dual-acting antiangiogenic gene therapy. Mol Ther Nucleic Acids. 2019;16:38–50.
- Csaky K, Curcio CA, Mullins RF, et al. New approaches to the treatment of age-related macular degenration (AMD). Experimental Eye Research; 2022. 221. 10.1016/j.exer.2022.109134